Literature DB >> 19023126

Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.

Deanna M Barch1, Cameron S Carter, Amy Arnsten, Robert W Buchanan, Jonathan D Cohen, Mark Geyer, Michael F Green, John H Krystal, Keith Nuechterlein, Trevor Robbins, Steven Silverstein, Edward E Smith, Milton Strauss, Til Wykes, Robert Heinssen.   

Abstract

This overview describes the goals and objectives of the third conference conducted as part of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. This third conference was focused on selecting specific paradigms from cognitive neuroscience that measured the constructs identified in the first CNTRICS meeting, with the goal of facilitating the translation of these paradigms into use in clinical trials contexts. To identify such paradigms, we had an open nomination process in which the field was asked to nominate potentially relevant paradigms and to provide information on several domains relevant to selecting the most promising tasks for each construct (eg, construct validity, neural bases, psychometrics, availability of animal models). Our goal was to identify 1-2 promising tasks for each of the 11 constructs identified at the first CNTRICS meeting. In this overview article, we describe the on-line survey used to generate nominations for promising tasks, the criteria that were used to select the tasks, the rationale behind the criteria, and the ways in which breakout groups worked together to identify the most promising tasks from among those nominated. This article serves as an introduction to the set of 6 articles included in this special issue that provide information about the specific tasks discussed and selected for the constructs from each of 6 broad domains (working memory, executive control, attention, long-term memory, perception, and social cognition).

Entities:  

Mesh:

Year:  2008        PMID: 19023126      PMCID: PMC2643950          DOI: 10.1093/schbul/sbn163

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  17 in total

1.  Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

Authors:  Stephen R Marder; Wayne Fenton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

Review 2.  The neurobiology of cognition in schizophrenia.

Authors:  Carol A Tamminga
Journal:  J Clin Psychiatry       Date:  2006-09       Impact factor: 4.384

Review 3.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

Review 4.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

Review 5.  Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia.

Authors:  Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

Review 6.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

Review 7.  Adrenergic targets for the treatment of cognitive deficits in schizophrenia.

Authors:  Amy F T Arnsten
Journal:  Psychopharmacology (Berl)       Date:  2003-12-19       Impact factor: 4.530

Review 8.  Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction.

Authors:  David A Lewis; David W Volk; Takanori Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

Review 9.  Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

Authors:  Joseph I Friedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

Review 10.  Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.

Authors:  Cameron S Carter; Deanna M Barch
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

View more
  53 in total

1.  [Neuroimaging markers: their role for differential diagnosis and therapeutic decisions in personalized psychiatry].

Authors:  O Gruber
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

Review 2.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

Review 3.  Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives.

Authors:  Martien J Kas; Jeffrey C Glennon; Jan Buitelaar; Elodie Ey; Barbara Biemans; Jacqueline Crawley; Robert H Ring; Clara Lajonchere; Frederic Esclassan; John Talpos; Lucas P J J Noldus; J Peter H Burbach; Thomas Steckler
Journal:  Psychopharmacology (Berl)       Date:  2013-09-19       Impact factor: 4.530

4.  The effects of CACNA1C gene polymorphism on spatial working memory in both healthy controls and patients with schizophrenia or bipolar disorder.

Authors:  Qiumei Zhang; Qiuge Shen; Zhansheng Xu; Min Chen; Lina Cheng; Jinguo Zhai; Huang Gu; Xin Bao; Xiongying Chen; Keqin Wang; Xiaoxiang Deng; Feng Ji; Chuanxin Liu; Jun Li; Qi Dong; Chuansheng Chen
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

Review 5.  Future classification of psychotic disorders.

Authors:  Wolfgang Gaebel; Jürgen Zielasek
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

6.  Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP).

Authors:  Megan St Peters; Ajeesh Koshy Cherian; Marc Bradshaw; Martin Sarter
Journal:  Behav Brain Res       Date:  2011-08-22       Impact factor: 3.332

7.  Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.

Authors:  Richard S E Keefe; Vicki G Davis; Nathan B Spagnola; Dana Hilt; Nancy Dgetluck; Stacy Ruse; Thomas D Patterson; Meera Narasimhan; Philip D Harvey
Journal:  Eur Neuropsychopharmacol       Date:  2014-06-28       Impact factor: 4.600

Review 8.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.

Authors:  Holly Moore; Mark A Geyer; Cameron S Carter; Deanna M Barch
Journal:  Neurosci Biobehav Rev       Date:  2013-09-30       Impact factor: 8.989

10.  Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different.

Authors:  A Owoso; C S Carter; J M Gold; A W MacDonald; J D Ragland; S M Silverstein; M E Strauss; D M Barch
Journal:  Psychol Med       Date:  2013-03-25       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.